Background & objective: The platinum-combination chemotherapy has been proved to be benefit to the patients with advanced non-small cell lung cancer (NSCLC), but the suitable regimen of chemotherapy has been much debated during the last decade. This study was designed to compare MIP regimen [mitomycin + ifosfamid + cisplatin], TP regimen [Taxol + cisplatin], and DP regimen [docetaxel + cisplatin] and to evaluate the efficacy of the three regimens in patients with advanced NSCLC.
Methods: Ninety-two patients were enrolled in this study, 32 for MIP, 30 for TP, and 30 for DP. The characteristics of patients were comparable except there were more stage IV patients and second chemotherapy patients in DP group.
Results: For MIP, TP, and DP groups, the objective response rates were 43.8%, 40%, and 46.7%, respectively; the median duration of survival were 11, 10, and 12 months respectively; the 1 year survival rate were 46%, 40%, and 50%, respectively. The major toxicities were bone marrow suppression, nausea, vomiting, and alopecia.
Conclusions: MIP, TP, and DP regimens are effective and safe chemotherapy protocols for the treatment of advanced NSCLC patients.